EMA Authorised: Xagrid (anagrelide) — Takeda Pharmaceuticals International AG Ireland

View source ↗

Summary

Anagrelide (Xagrid) has been authorized by EMA for essential thrombocythemia, with Takeda as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia

Drugs mentioned

• XAGRID®

Snippet

Status: Authorised. Therapeutic area: Thrombocythemia, Essential. MAH: Takeda Pharmaceuticals International AG Ireland. Decision date: 16/02/2023